How to buy ARCA biopharma stock

ARCA biopharma, Inc is a biotechnology business based in the US. ARCA biopharma shares (ABIO) are listed on the NASDAQ and all prices are listed in US Dollars. ARCA biopharma employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

ARCA biopharma share price

Use our graph to track the performance of ABIO stocks over time.

ARCA biopharma shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$3.22 - $10.25
50-day moving average	$3.72
200-day moving average	$4.14
Wall St. target price	$7.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-6.67

Buy ARCA biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ARCA biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ARCA biopharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ARCA biopharma financials

Gross profit TTM	$0
Return on assets TTM	-20.7%
Return on equity TTM	-35.98%
Profit margin	0%
Book value	$4.87
Market capitalisation	$49.6 million

TTM: trailing 12 months

Shorting ARCA biopharma shares

There are currently 556,722 ARCA biopharma shares held short by investors – that's known as ARCA biopharma's "short interest". This figure is 18.2% up from 471,152 last month.

There are a few different ways that this level of interest in shorting ARCA biopharma shares can be evaluated.

ARCA biopharma's "short interest ratio" (SIR)

ARCA biopharma's "short interest ratio" (SIR) is the quantity of ARCA biopharma shares currently shorted divided by the average quantity of ARCA biopharma shares traded daily (recently around 460100.82644628). ARCA biopharma's SIR currently stands at 1.21. In other words for every 100,000 ARCA biopharma shares traded daily on the market, roughly 1210 shares are currently held short.

However ARCA biopharma's short interest can also be evaluated against the total number of ARCA biopharma shares, or, against the total number of tradable ARCA biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ARCA biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 ARCA biopharma shares in existence, roughly 40 shares are currently held short) or 0.0387% of the tradable shares (for every 100,000 tradable ARCA biopharma shares, roughly 39 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ARCA biopharma.

Find out more about how you can short ARCA biopharma stock.

ARCA biopharma share dividends

We're not expecting ARCA biopharma to pay a dividend over the next 12 months.

Have ARCA biopharma's shares ever split?

ARCA biopharma's shares were split on a 1:18 basis on 3 April 2019. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ARCA biopharma shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for ARCA biopharma shares which in turn could have impacted ARCA biopharma's share price.

ARCA biopharma share price volatility

Over the last 12 months, ARCA biopharma's shares have ranged in value from as little as $3.22 up to $10.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ARCA biopharma's is 2.775. This would suggest that ARCA biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ARCA biopharma overview

ARCA biopharma, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. .

Frequently asked questions

• What percentage of ARCA biopharma is owned by insiders or institutions?

  Currently 0.258% of ARCA biopharma shares are held by insiders and 5.777% by institutions.

• How many people work for ARCA biopharma?

  Latest data suggests 11 work at ARCA biopharma.

• When does the fiscal year end for ARCA biopharma?

  ARCA biopharma's fiscal year ends in December.

• Where is ARCA biopharma based?

  ARCA biopharma's address is: 10170 Church Ranch Way, Westminster, CO, United States, 80021

• What is ARCA biopharma's ISIN number?

  ARCA biopharma's international securities identification number is: US00211Y5069

• What is ARCA biopharma's CUSIP number?

  ARCA biopharma's Committee on Uniform Securities Identification Procedures number is: 00211Y100